Pfizer Boost FY24 Outlook - Update

RTTNews | 81 dni temu
Stocktwits
Pfizer Boost FY24 Outlook - Update

(RTTNews) - While reporting financial results for the second quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings and revenue guidance for the full-year 2024.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.45 to $2.65 per share on revenues between $59.5 billion and $62.5 billion, with revenues of about $8.5 billion for Comirnaty, about $5 billion for Paxlovid and about $3.5 billion from legacy Seagen.

Previously, the company expected adjusted earnings in the range of $2.15 to $2.35 per share on revenues between $58.5 billion and $61.5 billion, with revenues of about $5 billion for Comirnaty, about $3 billion for Paxlovid and about $3.1 billion from legacy Seagen.

On average, 21 analysts polled by Thomson Reuters expect the company to report earnings of $2.38 per share on revenues of $60.70 billion for the year. Analysts' estimates typically exclude special items.

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer now expects to achieve full-year 2024 operational revenue growth of 9 to 11 percent, compared to 2023 revenues, up from 8 to 10 percent provided on January 30, 2024.

The company has launched a manufacturing optimization program with anticipated cost savings of approximately $1.5 billion by the end of 2027.

The company is also on track to deliver at least $4 billion in net cost savings by end of 2024 from previously announced cost realignment program.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tagi: PFE
Stocktwits
read more
Pfizer Launches Digital Platform PfizerForAll

Pfizer Launches Digital Platform PfizerForAll

Drug giant Pfizer Inc. (PFE) announced Tuesday the introduction of PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.
RTTNews | 53 dni temu
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews | 57 dni temu
Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
RTTNews | 149 dni temu
Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews | 159 dni temu
Pfizer Boost FY24 Adj. EPS Outlook - Update

Pfizer Boost FY24 Adj. EPS Outlook - Update

While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.
RTTNews | 171 dni temu
Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Inc. (PFE) announced Thursday the successful completion of its acquisition of biotechnology company Seagen Inc. (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
RTTNews | 310 dni temu
Narzędzia
Kalendarz ekonomiczny
Market Hours
Interest Rates
Holidays Calendar
Rynek Forex
Zmienność na rynku Forex
Korelacja na rynku Forex
Wiadomości Forex
forex analysis
Dane COT
Płynność
Kalkulatory Forex
Mapa termiczna Forex
Indicators Heatmap
Społeczność
Społeczność
System
Najpopularniejsze systemy
Strategie
Konkursy
Wykresy Forex
Nastroje na rynku Forex
Wskaźnik prognozy
Recenzje
Brokers
Prop Trading Firms
Usługi VPS
Dostawcy sygnałów
Usługi programistyczne EA
Affiliate Programs
Usługi brokerów PAMM
Usługi programu rabatowego
Platformy transakcyjne
Doradca
Kriptobirzhi
Trading Courses
Brokers
Spready na rynku Forex
Notowania brokera Forex
Swapy brokerów Forex
Wolumen brokera Forex
Akcje brokerów Forex Broker News
Platforma
Widgety
Funkcje
API
RSS
Stock Portfolio
Affiliate Software
Zaawansowane wykresy
Wsparcie
FAQ
Pomoc
Kontakt z nami
Zgłoś błąd!
O nas
Blog
© 2024 Myfxbook Ltd. Wszelkie Prawa Zastrzeżone.
Ostrzeżenie o wysokim ryzyku: handel walutami obcymi wiąże się z wysokim poziomem ryzyka, który może nie być odpowiedni dla wszystkich inwestorów. Dźwignia stwarza dodatkowe ryzyko i ryzyko straty. Zanim zdecydujesz się na handel walutami, dokładnie przemyśl swoje cele inwestycyjne, poziom doświadczenia i tolerancję ryzyka. Możesz stracić część lub całość początkowej inwestycji. Nie inwestuj pieniędzy, których nie możesz stracić. Zbadaj ryzyko związane z handlem walutami i zasięgnij porady niezależnego doradcy finansowego lub podatkowego, jeśli masz jakiekolwiek pytania. Wszelkie dane i informacje są dostarczane "tak, jak są" wyłącznie w celach informacyjnych i nie są przeznaczone do celów handlowych ani konsultacji. Wcześniejsze wyniki nie są wskaźnikiem przyszłych wyników.